Recent Finacing
Recent Raise
Fluoresentric commercializes XCR™, a patented nucleic acid amplification chemistry achieving ~5-minute DNA/RNA amplification with inhibitor resistance and reduced artifacts, compatible with existing PCR platforms and point-of-care instruments.
Focus Areas
Funding round